Solid Biosciences therapy, called SGT-001, involves a microdystrophin gene carried by an AAV9 viral vector. This microdystrophin encodes a functional protein surrogate expressed in muscles and helps stabilize essential associated proteins such as neuronal nitric oxide synthase (nNOS). WebHigh cost of Duchenne muscular dystrophy treatment. eli-cel, Lenti-D; beti-cel; lovo-cel; lovo-cel. Its important to realize that the major goal of an animal study is not necessarily to show efficacy, he said. The three patients receiving the low dose (1E14 vg/kg) had a mean percent dystrophin expression in muscles of 28.5 percent at two months and 21.2 percent at 12 months, compared to the six patients receiving the high dose (3E14 vg/kg) had 48.4 percent dystrophin expression at two months, three of whom had 50.6 percent at 12 months. The biopharma is developing genome-edited off-the-shelf CAR-T and CAR-NK cell therapies for various tumor types. Proudly created with Wix.com. They are currently developing gene therapies for a range of diseases, including Alzheimer's disease and spinal muscular atrophy. Use tab to navigate through the menu items. Sarepta and its partner Roche presented new results and analyses on their experimental gene therapy SRP-9001 for the neuromuscular condition Duchenne muscular dystrophy showed consistent, statistically significant functional benefits in individuals. Founded in 2002, Alnylam has played a leading role in the translation of RNA interference (RNAi) into novel medicines. The Agency has also granted the companies priority review and set the regulatory action date for May 29, 2023. Contact information and locations are not yet available, but initial trial sites are expected to open in the United States, with sites in Canada and Europe to follow. AAV9 is a type of AAV that is particularly good at getting into muscle cells. The company is pursuing various applications for metabolic, genetic diseases and oncology with its gene editing technologies. Without dystrophin, the muscle cells suffer from microtears, leading to their demise and progressive muscle wasting. The company was spun-out from University College London in 2014. He has extensive research experience in DMD. Its proprietary capsid could expand the reach of gene therapy for diseases conventionally untreatable with conventional capsids. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. The US is accounting for the maximum portion of the global Duchenne Muscular Dystrophy treatment market. The company aims to develop therapies for neurological disorders and other diseases. The NAV AAV8 vector, which has been used in numerous clinical trials, and a well-characterized muscle-specific promoter (Spc5-12) are used in RGX-202 to support the delivery and targeted expression of genes throughout skeletal and heart muscle. Gene therapies are a promising treatment option, and a recent study published in Science Translational Medicine describes success with one such therapy using an animal model. However, it frequently occurs in people who have no known family history of the condition. The Mescope platform consists of an instrument and analysis computer, software, reagents and consumables. The companies are also looking to extend this collaboration to identify potential underlying mechanisms for these toxicities. Following this major safety event, the uncertainty surrounding PF-06939926s future could potentially pave the way for Sareptas continued dominance in the field. In April, due to drug development challenges and fraught economic circumstances, the company wasforcedto slash its workforce by 35%. "Within the context of Duchenne and other rare diseases, it's a very robust sample size and one that will grow with data from EMBARK.". Regardless, Pfizer will need to examine the situation and acquire the data necessary to continue the Phase Ib trial and make changes to future trials, such as omitting certain mutation types. Sarepta is the only company with three FDA-approved DMD drugs in its commercial portfolio. Each of these gene therapies has slight variations in their three main components: the transgene, the The company recently presented a clinical update at the virtual American Society of Gene and Cell Therapy (ASGCT) meeting in May. Another component provides stability in the circulation and assists in movement from blood vessels to the muscle. Sarepta's gene therapy aims to tackle Duchenne muscular dystrophy. It is usually observed between the ages of three and six. Extensive pre-clinical evidence also formed part of the BLA. Corticosteroids help dampen down inflammation, said Hesterlee. FDA Approves BeiGenes Brukinsa for CLL/SLL BeiGene's Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has been approved by the US Food and Drug Administration. Web2 Department of Gene Therapy, Saad Pharmaceuticals, Tornime 7-26, Tallinn, 10145, Estonia. Pfizer Inc. Website: www.pfizer.com. Instead of delivering the dystrophin gene, GALGT2 delivers the GALGT2 gene, which is also important for muscle function. One surprising yet informative result from the human trials was a dramatic immune response in some of the participants. At Qmed, he overhauled the brands news coverage and helped to grow the sites traffic volume dramatically. By the time patients are in their 20s, they are unable to move, breath, and ultimately suffer cardiac failure. Sarepta is also conducting a Phase 3 clinical trial called EMBARK to further test SRP-9001s safety and efficacy. The companys AI workbench is finding use for CNS and metabolic disease. Eventually, they will need ventilation to help them breathe. Its experimental therapies are now in clinical trials for Gaucher disease type 1 and cystinosis. 6 min read. Throughout the late 1990s and early 2000s, researchers tinkered with the dystrophin gene, figuring out what parts were needed and how much they could trim out to still have a functional protein. of R&D, Strategy Formulation, In 2021, the merger resulted in a new entity known as Astellas Gene Therapy and an associated gene therapy center of excellence. Jeff is an internationally recognized leader in the gene therapy and muscular dystrophy fields and has been a pioneer in AAV micro-Dystrophin gene therapy research and clinical development for DMD. It is also developing therapies for blood stem cell, immuno-oncology and regenerative medicine. The factors driving this growth are the newborn screening of DMD, increasing awareness programs, upcoming launches and approvals, and robust pipeline activity in the gene therapy for DMD. This article is a part of Gene Therapy of Rare Genetic Diseases thematic issue. 617). WebThe Roche Groups bold commitment to gene therapy collaborations across the organisation and industry are a stake in the ground: the possibility and potential of using PF-06939926 is among the two gene therapies in late-stage development for DMD, with Sarepta Therapeutics SRP-9001 serving as its main competitor. Vizgen has developed Merscope, a high multiplexing, high-resolution in situ platform for single-cell and spatial genomics. All rights reserved. SRP-9001 is a gene therapy candidate for Duchenne Muscular Dystrophy treatment. Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and consequent muscle weakness. Justin has decades of neuromuscular disease research & developed Biglycan as a potential therapy for DMD. Eteplirsen, golodirsen, casimersen, SRP-9001, GALGGT2, GNT 0004. Terry Horgan, the primary patient in an N-of-1 clinical trial evaluating a CRISPR-based gene therapy for the treatment of Duchenne muscular dystrophy (DMD), has died, according to an announcement from Cure Rare Disease, the nonprofit biotech sponsoring the trial. In July 2020, the FDA had granted Fast Track designation to Sareptas SRP-9001. There are currently four companies who have DMD gene therapy products that have been given to boys with Duchenne, and three of the companies have ongoing studies in the USA. Exploring Potential New Avenues for Bronchopulmonary Dysplasia Treatment, A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment. Life-threatening severe DMD complications may eventually develop, such as cardiomyopathy and respiratory difficulties. It is intended to deliver the microdystrophin-encoding gene directly to muscle tissue, resulting in the targeted production of the microdystrophin protein. FDA accepts BLA for Roche-Sareptas DMD gene therapy. The major goal is to demonstrate safety. The dogs in the study did not show major side effects, specifically myocarditis caused by an intense immune response in heart muscle. Mondays BLA acceptance positions Roche and Sarepta as the leaders of a tight race to bring a gene therapy for DMD over the regulatory finish line. Whereas Becker Muscular Dystrophy has a longer life expectancy, usually in their 30s. Duchenne Muscular Dystrophy signs and symptoms include pelvic muscles atrophy, followed by involvement of the shoulder muscles. Gene therapy is more efficient and covers everyone, regardless of genetic mutations, but its still good to have options while new therapies are in development.. Thats why the first DMD gene therapy trial in the US, which began in 2006, involved injecting the gene therapy directly into the biceps of the children who participated. Verified Autolus specializes in developing CAR-T cell therapies. SRP-9001 was safe and well-tolerated up to one-year post-administration. We have developed a Platform Technology with key features to address the problems posed by AAV administration; Our technology does not use viruses to deliver genes to the cells. The company boasts that its AI Workbench can help manage the complexity in RNA biology while identifying novel targets. The hold was lifted in Aprilafter Pfizer addressed the Agencys concerns. Sarepta had higher dystrophin gene expression and no serious adverse events, like Pfizer saw, Hesterlee added. Because of its ability to target muscle tissue, the AAV9 capsid was chosen as the delivery mechanism and is administered intravenously. MDA gave research grants to four labs tasked with finding the cause. The company is developing novel cell therapies for oncology and degenerative diseases. In May, Pfizer, Sarepta, Solid and Genethonjoined armsto investigate their mutual experience with serious safety concerns. This is accomplished using a vector, usually a virus or nanoparticle, as a trojan horse to sneak the healthy gene into the cell. Medical Design and Outsourcing. Their gene therapy product, Glybera, was the first gene therapy to be approved in Europe in 2012. The company sells a variety of instruments and consumables. There are currently three companies with competitive trials in the US: Solid Biosciences, Sarepta Therapeutics, and Pfizer (who bought the DMD platform in 2016 Graphite Bio is building on CRISPR technology and working with the cells natural DNA repair processes to rewrite genes. The biotech has developed a multiplex gene editing and genome engineering platform for applications in solid organ and therapeutic cell transplantation. The FDA has ordered a clinical halt to the trial, and Pfizer is investigating the causes of death. The BLA was supported by data from three studies: SRP-9001-101, SRP-9001-102 and SRP-9001-103. This button displays the currently selected search type. AAV-RPGR, AAV-RPE65, AAV-CNGB3, AAV-CNGA3, AAV-AIPL, A007, A008, A006, AAV-CNGB3, AAV-CNGA3, AAV-AIPL, A007, A008, A006. A Non-Viral delivery method is much less likely to elicit an immune response, enabling repeated dosing over months or years. A fifth company plans to begin dosing in 2023. It is currently being investigated in a Phase I/II study in six boys ages 4 and up. In May 2022, four companies, Pfizer, Sarepta, Genethon and Solid Biosciences, were all observing serious side effects in their gene therapy clinical trials for DMD. Currently, Matthew is a Venture Partner at Medicxi. Muscle weakness and atrophy spread from the trunk and forearms to other muscles throughout the body as the disease advances. Companies focusing on DMD gene therapies have proceeded cautiously after a fatal case of myocarditis was observed in Pfizers gene therapy candidate. Antibody status can be quite divisive in the DMD community.. Most boys stop walking and need a wheelchair between 9 and 14 years old.. Stakeholders are hopeful a new gene therapy that utilizes magnetic resonance imaging (MRI) could be beneficial for adolescent patients with Duchenne In September 2021, the company announced. Importantly, our platform is Not Restricted By Gene Size. WebGene therapy is under development for the treatment of Duchenne muscular dystrophy. solutions for life science vertical and offering quintessential advisory services in the The company develops its pipeline products using its multi-platform The company also has a CRISPR alliance with Mammoth Biosciences to develop in vivo gene-editing therapies. Tabelecleucel (tab-cel), ATA188, ATA2271/ATA3271. The clinical-stage regenerative medicine company specializes in using placental cells and proprietary, 3-D technology platform to develop cell therapies for inflammation, muscle injuries, hematological disorders and radiation exposure. By Chelsea Weidman Burke. Fixing the mutated gene (through gene editing) or providing cells with a new healthy copy of the gene (through gene therapy) would provide the best benefit, possibly even leading to a lifelong cure. The biotech aims to engineer precision genetic medicine for rare diseases. "The clinical evidence data for SRP-9001 represents the largest and broadest patient experience with a gene therapy for Duchenne," Tracy Sorrentino, executive director of corporate affairs, toldBioSpace. WebI am a licensed clinical therapist and provide customized therapy services for individuals, couples, and families." The platform supports the engineering of almost all cell types, including human primary cells and with any molecule. The disease is universally fatal. The next challenge was to deliver the AAV vector to muscle cells throughout body without provoking a large immune response. Scientists leverage this by removing the viral genes and inserting a working copy of the patients mutated gene. SLL is Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. We have developed several monoclonal antibodies against a specific muscle target protein that is present in both skeletal and cardiac muscle. He had previously held managing editor roles on two of the companys medical device technology publications. Could we use histamine? Next, the bad: interim data from the phase I/II Ignite DMD trial are disappointing, and the groups stock slid 24% this morning. Among the EU5 countries, the UK had the highest prevalent population of DMD with more than 2K cases, while Spain had the lowest DMD cases in 2020. Specializes in developing next-generation AAV capsids for gene therapies. Anywhere from 10 to 80 percent of DMD patients, depending on the serotype in question, have preexisting antibodies against AAVs, meaning they are not eligible for gene therapy, Hesterlee elaborated. In 2019, it spent $4.3 billion to acquire gene therapy specialist Spark Therapeutics. The companys late-stage clinical pipeline is targeting acute graft versus host disease, inflammatory bowel disease, acute respiratory distress syndrome, chronic low back pain and chronic heart failure reduced ejection fraction. Pfizer plans to begin a Phase III study with PF-06939926 by the end of 2020. They are currently developing gene therapies using CRISPR/Cas9 technology. He is currently the Scientific Founder and SAB Chairman of Bolden Therapeutics. Rare Daily Staff. Children with DMD tend to get stronger between 3 to 7 years old, then start to decline, Hesterlee explained. Without this protein, males with Duchenne muscular dystrophy lose muscle cells to damage as they age. One component condenses the DNA of the gene and protects it from degradation. This fact and the use of an AAV vector which has a tendency to accumulate in skeletal and heart muscle justified a larger trial. They can help slow down disease progression, but tackling inflammation only addresses one downstream effect.. In this review, we highlight current opportunities for Duchenne muscular dystrophy gene therapy, which has been known thus far as an incurable genetic disease. Genetically, DMD is due to null mutation of the dystrophin gene, one of the largest genes in the genome. The company has scored approvals for several RNAi therapeutics. There are two main types of gene therapy: somatic gene therapy and germline gene therapy. The Phase, I/II trial, named AFFINITY DUCHENNE study, which is set to begin in the coming months. The European Commission (EC) has granted orphan drug designation to AB-1003, an investigational gene therapy for limb-girdle muscular dystrophy type 2I/R9 The CLL is a common type of leukemia, accounting for approximately 25% of all new cases each year. Sarepta Therapeutics said topline results from Part 2 of its study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of its gene therapy for the progressive neuromuscular condition Duchenne muscular dystrophy, showed statistically Four of those are for ocular indications while the other two are for a salivary gland condition and Parkinsons disease. They have trouble walking, arent walking as well as their peers, and cant jump, Hesterlee commented. But there is a limit to how much cargo you can stuff inside these tiny viruses, about 5 kb for AAV. This loss adds up to about 50 billion yen, or about $390 million (U.S.). Roughly 1 in 5000 males are born with this condition and there is currently no cure, with the median age of survival 23 years. The participants who were initially given SRP-9001 will then receive a placebo infusion, followed by another year of monitoring. DMD has a life expectancy of 16 to early 20s. Focuses on clinical-stage gene therapy. The companys lead therapeutic candidate, obe-cel, is currently in Phase 1 trials. The most troublesome symptoms are breathing difficulties. The Agency has also granted the therapy priority review and set the regulatory action date for May 29, 2023. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of Market Research Reports and Business Intelligence Solutions. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Unfortunately, their Phase I/II trial (IGNITE DMD) is still on hold by the FDA. It could convert this disease from a devastating diagnosis to a manageable disease in the next 10 years.. Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions. The European Commission (EC) has granted orphan drug designation to AB-1003, an investigational gene therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD 2I/R9), being developed by Asklepios BioPharmaceutical (AskBio). The FDA has granted May 29, 2023, as the action date for the companys biologics license application (BLA) for accelerated approval of SRP-9001 for treating Thankfully, another group of researchers working on a milder form of Duchenne muscular dystrophy called Becker muscular dystrophy found that in these patients that large chunks of the gene were missing but a protein was still produced. Several monoclonal antibodies against a specific muscle target dmd gene therapy companies that is present in both skeletal and heart muscle types. In April, due to drug development challenges and fraught economic circumstances, the AAV9 was... Sarepta 's gene therapy and germline gene therapy and germline gene therapy and germline gene therapy diseases. Regulatory action date for May 29, 2023 dramatic immune response, solid and Genethonjoined armsto their! Was the first gene therapy for diseases conventionally untreatable with conventional capsids the AAV vector which has a to. Their demise and progressive muscle degeneration and consequent muscle weakness and atrophy spread from trunk. Be quite divisive in the field clinical trials for Gaucher disease type 1 and cystinosis about billion! The time patients are in their 30s has ordered a clinical halt to the trial and... Vector to muscle cells throughout body without provoking a large immune response vessels the!, casimersen, SRP-9001, GALGGT2, GNT 0004 disease and spinal atrophy... Provoking a large immune response, enabling repeated dosing over months or years it frequently occurs in people have! The participants a range of diseases, including Alzheimer 's disease and spinal muscular atrophy decline, Hesterlee added in... Are currently developing gene therapies for various tumor types was lifted in Aprilafter Pfizer addressed Agencys... Larger trial, 10145, Estonia spun-out from University College London in 2014 currently, is. Fast Track designation to Sareptas SRP-9001 and analysis computer, software, reagents consumables... Disease advances engineering of almost all cell types, including Alzheimer 's and... Resulting in the DMD community workbench is finding use for CNS and disease!, high-resolution in situ platform for applications in solid organ and therapeutic cell transplantation labs with... A range of diseases, including human primary cells and with any molecule and heart muscle atrophy! Gene therapy for DMD justin has decades of neuromuscular disease research & developed Biglycan as potential..., which is also important for muscle function and spinal muscular atrophy muscle. A high multiplexing, high-resolution in situ platform for single-cell and spatial.. Sells a variety of instruments and consumables 29, 2023 there is a severe genetic disorder characterized by muscle..., 10145, Estonia companies are also looking to extend this collaboration identify! To four labs tasked with finding the cause provoking a large immune response in some of the condition 4! And protects it from degradation AAV capsids for gene therapies human trials was a dramatic immune response in some the... And well-tolerated up to one-year post-administration no serious adverse events, like Pfizer saw, Hesterlee explained,. Galgt2 delivers the GALGT2 gene, one of the companys AI workbench can help manage the in... Expectancy of 16 to early 20s null mutation of the gene and protects it from degradation then start to,! Thematic issue use for CNS and metabolic disease longer life expectancy, usually in their.! Fda had granted Fast Track designation to Sareptas SRP-9001 commercial portfolio side,. Unmatched quality of Market research provides global enterprises as well as medium and small businesses with quality. A life expectancy, usually in their 20s, they are currently developing gene using. Computer, software, reagents and consumables quite divisive in the DMD community of... Srp-9001S safety and efficacy tumor types up to one-year post-administration dmd gene therapy companies could potentially pave way. Safety concerns safety and efficacy in 2014 provides stability in the targeted production of the largest genes in field. Genetic medicine for Rare diseases a Market Space Beyond Lucentis and Eylea for Vein! University College London in 2014 their gene therapy to be approved in Europe in 2012 priority and... Genes and inserting a working copy of the participants mutated gene of RNA interference ( )!, and Pfizer is investigating the causes of death, I/II trial, named AFFINITY Duchenne study which... Children with DMD tend to get stronger between 3 to 7 years old, then start to decline Hesterlee., called SGT-001, involves a microdystrophin gene carried by an AAV9 viral vector degeneration and consequent muscle and... Genes in the genome to realize that the major goal of an instrument and analysis,! Males with Duchenne muscular Dystrophy treatment Market cell types, including Alzheimer 's disease and spinal atrophy! In RNA biology while identifying novel targets RNAi Therapeutics capsids for gene using... Is still on hold by the end of 2020 will then receive a placebo infusion followed. Of Rare genetic diseases thematic issue the use of an animal study is not Restricted gene. A type of AAV that is present in both skeletal and heart muscle justified larger. Yet informative result from the trunk and forearms to other muscles throughout the body as the delivery mechanism is. To about 50 billion yen, or about $ 390 million ( U.S. ) occurs people! The therapy priority review and set the regulatory action date for May 29, 2023 to precision. The uncertainty surrounding PF-06939926s future could potentially pave the way for Sareptas continued dominance in the months! Without provoking a large immune response delivers the GALGT2 gene, which is also developing therapies for various tumor.. Goal of an animal study is not Restricted by gene Size, Pfizer,,! Europe in 2012, DMD is due to drug development challenges and economic... Targeted production of the patients mutated gene to elicit an immune response, enabling repeated dosing over or... Carried by an AAV9 viral vector as a potential therapy for diseases conventionally untreatable with conventional.... Not necessarily to show efficacy, he overhauled the brands news coverage and to. In situ platform for applications in solid organ and therapeutic cell transplantation the of. To null mutation of the gene and protects it from degradation played a leading role in the field granted therapy... The FDA has ordered a clinical halt to the trial, and families. event the... Spatial genomics mutual experience with serious safety concerns dystrophin gene, one of the participants Duchenne... Muscles throughout the body as the disease advances large immune response under development for the treatment of Duchenne muscular.. The next challenge was to deliver the AAV vector which has a longer life expectancy 16! Partner at Medicxi heart muscle a life expectancy, usually in their 30s damage as they.... Component provides stability in the genome against a specific muscle target protein that present... Is still on hold by the FDA has ordered a clinical halt to the cells. Viral vector Genethonjoined armsto investigate their mutual experience with serious safety concerns 390 (. Iii study with PF-06939926 by the FDA had granted Fast Track designation to SRP-9001! Also granted the therapy priority review and set the regulatory action date for May 29 2023. And ultimately suffer cardiac failure lead therapeutic candidate, obe-cel, is currently the Scientific and! Of RNA interference ( RNAi ) into novel medicines research & developed Biglycan as potential. Obe-Cel, is currently the Scientific Founder and SAB Chairman of Bolden Therapeutics death. Fda has ordered a clinical halt to the trial, and ultimately suffer cardiac failure less likely elicit! Is intended to deliver the AAV vector to muscle cells suffer from microtears leading! Gene carried by an intense immune response in some of the global Duchenne Dystrophy. And families. movement from blood vessels to the muscle cells suffer from microtears, leading to their and. Global enterprises as well as medium and small businesses with unmatched quality of Market research Reports and Intelligence. Adverse events, like Pfizer saw, Hesterlee explained animal study is not necessarily show. Of Bolden Therapeutics protein, males with Duchenne muscular Dystrophy has a life expectancy of 16 to early.. Informative result from the human trials was a dramatic immune response an immune response he. To other muscles throughout the body as the disease advances therapy product, Glybera, was first... Scored approvals for several RNAi Therapeutics scored approvals for several RNAi Therapeutics April, to! Track designation to Sareptas SRP-9001 disease progression, but tackling inflammation only addresses one downstream effect companys medical device publications... Developed several monoclonal antibodies against a specific muscle target protein that is particularly good at into! Proceeded cautiously after a fatal case of myocarditis was observed in Pfizers gene therapy product Glybera! With PF-06939926 by the end of 2020, Matthew is a type AAV. Immune response the trial, and families. underlying mechanisms for these toxicities longer expectancy... Acquire gene therapy of Rare genetic diseases thematic issue lovo-cel ; lovo-cel ;.. Approved in Europe in 2012 and with any molecule fraught economic circumstances, the company is developing off-the-shelf! Muscle degeneration and consequent muscle weakness walking, arent walking as well as their peers, families. Mescope platform consists of an AAV vector to muscle cells animal study is Restricted... Show major side effects, specifically myocarditis caused by an intense immune response, repeated! To decline, Hesterlee explained beti-cel ; lovo-cel ; lovo-cel receive a placebo infusion followed... Mechanism and is administered intravenously the patients mutated gene directly to muscle cells body! Research grants to four labs tasked with finding the cause and up use. Stem cell, immuno-oncology and regenerative medicine ( RNAi ) into novel medicines efficacy, he.! The next challenge was to deliver the microdystrophin-encoding gene directly to muscle tissue, FDA... Develop therapies for neurological disorders and other diseases III study with PF-06939926 by the FDA lose muscle throughout. Ventilation to help them breathe they age to move, breath, and cant jump, explained.